Argent BioPharma secures first FDA milestone for CannEpil® veterinary program
Argent BioPharma (ASX: RGT) has advised that the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM) has established Investigational New Animal Drug (INAD) File No. 14145 for the CannEpil® veterinary development programme.
The milestone represents the first formal FDA regulatory milestone for the CannEpil® veterinary programme, which targets cancer-related pain in companion animals, beginning with canine oncology.
The programme is being advanced by Argent’s global CannEpil® licensing partner, Endovia Health Sciences, together with Lupvindol Biosciences. It fits within the Company’s capital-efficient licensing model, where partners fund and execute development while Argent retains long-term upside.
For investors, the file establishment marks tangible progress from a commercial agreement into regulatory execution, moving the veterinary strategy into formal engagement with the U.S. regulator.
When big ASX news breaks, our subscribers know first
What the INAD file means — and what it doesn’t
An Investigational New Animal Drug (INAD) file is the regulatory framework that enables formal interaction with FDA-CVM. It provides the structure under which a veterinary drug candidate can progress through development planning, required studies, manufacturing activities and regulatory submissions.
The INAD framework enables:
-
Product development planning
-
Required preclinical and clinical studies
-
Manufacturing activities
-
Regulatory submissions in support of potential future approval
Importantly, establishment of an INAD file does not constitute FDA approval, Conditional Approval, confirmation of product safety or efficacy, or authorisation to commercially market CannEpil® in the United States.
Why it still matters: the file opens a defined regulatory pathway and provides a structured framework for the next stages of development. The programme is intended to progress through FDA-CVM under the Minor Use / Minor Species (MUMS) and Conditional Approval pathways, subject to ongoing regulatory engagement and successful completion of required development activities.
Initial focus on companion-animal oncology and the team behind it
Endovia Health Sciences (formerly Splash Beverage Group), Argent’s exclusive global CannEpil® licensing partner, has advised that the initial veterinary development programme will focus on the management of cancer-related pain in companion animals, beginning with canine oncology.
Lupvindol Biosciences will lead the scientific, pharmaceutical development and FDA regulatory activities associated with the programme.
The Lupvindol programme is led by Dr Hunter Land, who was GW Pharmaceuticals’ first full-time U.S. research and development employee. Dr Land participated in the development of Epidiolex®, the first FDA-approved plant-derived cannabinoid medicine, as well as Sativex®.
Experienced cannabinoid drug-development leadership adds credibility as the programme moves through the practical challenges of regulatory execution.
Why this matters for Argent BioPharma shareholders
The establishment of the INAD file validates Argent’s capital-efficient licensing strategy, under which experienced partners fund and execute development while the Company retains the underlying economics.
The CannEpil global licensing deal struck with Splash Beverage Group in July 2026 structured the commercial relationship that now underpins this regulatory milestone, with Argent retaining full IP ownership and a 15% net revenue royalty in exchange for Splash assuming all development obligations.
Argent retains ownership of the underlying CannEpil® intellectual property, manufacturing participation and a perpetual 10% royalty on veterinary revenues. This creates an additional potential value stream from an asset originally developed for human drug-resistant epilepsy.
| Milestone | What It Is | Argent’s Retained Interest | Investor Significance |
|---|---|---|---|
| INAD File No. 14145 established | First formal FDA-CVM regulatory file for the veterinary programme | IP ownership retained | Opens a defined U.S. regulatory pathway |
| Initial indication | Cancer-related pain in companion animals, beginning with canine oncology | Perpetual 10% royalty on veterinary revenues | Targets a specific companion-animal market |
| Development partners | Endovia Health Sciences and Lupvindol Biosciences | Manufacturing participation | Partners fund and execute development |
| Argent’s economics | Licensing model combining IP, manufacturing and royalties | IP, manufacturing and long-term royalty economics | Additional value stream with limited capital outlay |
Roby Zomer, Chairman
“The establishment of INAD File No. 14145 demonstrates tangible progress from commercial agreement to regulatory execution.
For Argent BioPharma, this is exactly how our licensing model is intended to work. We retain ownership of the underlying intellectual property, manufacturing participation and long-term royalty economics, while experienced partners fund and execute the development and commercialisation pathway.
There remains substantial development work ahead and the INAD does not represent FDA approval.”
The road ahead
The programme is intended to progress through FDA-CVM under the MUMS and Conditional Approval pathways, subject to ongoing regulatory engagement and the successful completion of required development activities.
Substantial development work remains, and the establishment of the file does not represent FDA approval.
The veterinary programme adds to Argent’s broader positioning as a revenue-generating specialty biopharmaceutical company, anchored by CimetrA®, with a stated pathway toward expansion into the United States capital markets.
The Aquiol licensing agreement signed with MGC Derma in May 2026 illustrates the same capital-efficient model at work across Argent’s portfolio, combining a fixed monthly payment with a revenue-linked royalty while leveraging existing technology without new development expenditure.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market and click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.